AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer

[Mary Brown]

Medical technology provider AngioDynamics, Inc. has officially announced the appointment of healthcare industry leader Eric Honroth as President, Chief Executive Officer, and member of the Board of Directors. Securing executive leadership under the AngioDynamics Eric Honroth CEO transition positions the company to accelerate its next growth phase as it expands its portfolio of minimally invasive medical devices. Honroth succeeds Jim Clemmer, who is retiring after a ten-year tenure as President and CEO.

The executive transition follows a comprehensive search scaling conducted by the Board of Directors to identify a leader with extensive experience medical device businesses, driving commercial execution, and managing international operations. Honroth brings over two decades of global MedTech leadership experience, equipping the organization with deep domain expertise across vascular access, peripheral vascular therapies, and oncology technologies.

Over Two Decades of Global MedTech Leadership​

Prior to joining AngioDynamics, Eric Honroth built a distinguished record of executive leadership across prominent multinational medical technology organizations. His operational background includes large-scale commercial restructuring, global supply chain optimization, and market development across North American, European, and Asian healthcare markets.

Throughout his career, Honroth has led cross-functional teams in bringing specialized interventional therapies from regulatory approval to widespread clinical adoption. His experience in managing high-growth medical device portfolio aligns directly with AngioDynamics' strategic focus on advancing innovative clinical solutions for complex vascular and oncological conditions.

Driving Commercial Strategy and MedTech Innovation​

AngioDynamics has contained a multi-year portfolio transformation, transitioning toward high-margin, high-growth technology segments such as its MedTech division. The company's core focus areas include non-thermal irreversible electroporation systems, mechanical thrombectomy technologies, and specialized vascular access solutions.

Under Honroth's leadership, AngioDynamics will focus on expanding its market presence and targeting global commercial operations. Key priorities driving the organization's strategic vision include:

• Expanding Global Commercial Execution: Accelerating direct sales reach and distributor partnerships across key international healthcare markets.
• Scaling High-Growth MedTech Platforms: Driving adoption of core interventional systems, including the NanoKnife system and AAlphaVac thrombectomy technologies.
• Optimizing Operational Efficiency: Enhancing manufacturing throughput, supply chain resilience, and disciplined capital allocation.
• Advancing Clinical Evidence Generation: Investing in post-market clinical studies to demonstrate long-term patient outcomes and secure expanded reimbursement coverage.

Ensuring Smooth Leadership Transition and Operational Continuity​

Outgoing CEO Jim Clemmer led AngioDynamics through a pivotal era of restructuring, reshaping its business model to focus on higher-growth, tech-driven medical devices. To maintain business continuity, Clemmer will work closely with Honroth during the transition period, ensuring seamless execution across commercial channels, ongoing clinical trials, and regulatory filings.

Executive leadership at AngioDynamics emphasized that welcoming Honroth as CEO marks an exciting milestone as the firm translates recent strategic transformation efforts into durable top-line growth and long-term shareholder value.

Positioning for Long-Term Growth in Minimally Invasive Healthcare​

As health systems worldwide prioritize minimally invasive procedures that reduce hospital length of stay and lower overall care delivery costs, demand for advanced interventional tools continues to rise. By pairing an established portfolio of specialized devices with proven executive commercial leadership, AngioDynamics is well-positioned to expand its footprint across fast-growing clinical sectors.

The appointment of Eric Honroth as President and CEO reflects AngioDynamics' commitment to delivering innovation that improves patient outcomes. Combining disciplined operational management with targeted market expansion, the enterprise remains dedicated to shaping the future of tech-enabled interventional care.

CXO Insiders is a platform for C-suite leaders, offering expert insights, industry trends, and strategic guidance. It covers leadership, technology, marketing HR and operations to support executive decision-making.

Read related news - https://cxoinsiders.com/henry-schein-names-emmanuel-caprais-as-new-cfo/